Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Brian L. Hillcoat"'
Autor:
Lorraine K. Webster, Brian L. Hillcoat, Ian N. Olver, Robert G. Sephton, James F. Bishop, Kerrie H. Stokes
Publikováno v:
Cancer Chemotherapy and Pharmacology. 45:55-58
This study investigated the pharmacokinetics and activity of gallium nitrate in non-small cell lung cancer when 700 mg/m2 was given as a 30-min infusion with prehydration every 2 weeks. Gallium was measured in plasma and urine using flameless atomic
Autor:
Brian L. Hillcoat
Publikováno v:
Drug Information Journal. 31:1395-1400
The Australian Guidelines for the Registration of Drugs recommend the contents and format of applications to register biologicals in Australia. This follows European guidelines and the European Union (EU) format is preferred. Registration does not re
Autor:
Lorraine K. Webster, Brian L. Hillcoat, David P. Buxton, Alison M. James, Tracey L. Williams, Robin J. Thomson, Ian A. G. Roos, Glen B. Deacon, Laurence P. G. Wakelin
Publikováno v:
Monash University
The platinum(II) organoamides [Pt(NRCH2)2L2] (L = pyridine (py), R = p-HC6F4, C6F5,p-IC6F4,p-CIC6F4,p-C6F5C6F4; L = 4-methylpyridine, R = p-HC6F4) and [Pt(NRCH2CH2NR')(py)2] (R = p-HC6F4, R' = C6F5, p-BrC6F4, or p-MeC6F4) inhibit the growth of murine
Publikováno v:
Cancer Chemotherapy and Pharmacology. 25:411-417
Our studies on the mechanism of resistance of the murine leukemia L1210-PDD line to cis-dichlorodiammineplatinum(II) (cis-DDP) have not shown why it is 10-fold more resistant to the drug than the L1210 line. For this reason we investigated metallothi
Autor:
Danny Rischin, C Riley, Brian L. Hillcoat, Andrew G. Östör, Warren M. McNaughton, Denys W. Fortune
Publikováno v:
Pathology. 25(3)
A patient with adenocarcinoma of the rectum containing germ cell elements in the form of endodermal sinus tumor and choriocarcinoma is described, believed to be the first such tumor reported in the literature. The serum levels of alpha-fetoprotein an
Autor:
Brian L. Hillcoat, James F. Bishop, Theodore W. Guentert, Phillip A. Reece, Raymond G. Morris, Ian N. Olver
Publikováno v:
American journal of clinical oncology. 13(4)
Doxifluridine (5'-dFUR) is a prodrug of 5 fluorouracil (5-FU) synthesized in an attempt to improve the therapeutic index compared with 5-FU. In this phase I study, cohorts of three patients were treated by a 5-day continuous infusion with the dose in
Autor:
Raymond G. Morris, Thedore W. Guentert, Phillip A. Reece, Ian N. Olver, Heather S. Hill, Brian L. Hillcoat, James F. Bishop
Publikováno v:
Cancer chemotherapy and pharmacology. 25(4)
Doxifluridine (5'-deoxy-5-fluorouridine, 5'-dFUR) metabolism has been reported to be saturable and associated with a fall in clearance of the drug as the dose is increased. The aim of the present study was to determine the disposition of 5'-dFUR and
Autor:
Brian L. Hillcoat
Publikováno v:
Medical Journal of Australia. 169:69-70
Autor:
Brian L. Hillcoat
Publikováno v:
Medical Journal of Australia. 158:657-658
Autor:
Stuart-Harris R, Derek Raghavan, R Aroney, Brian L. Hillcoat, In Olver, David Ball, George Morstyn, Richard M. Fox, Jf Bishop, Richard F. Kefford
Publikováno v:
Investigational New Drugs. 5:37-136